Shares of Inovio Pharmaceuticals ($INO) slipped nearly 2% on Thursday afternoon ahead of the company’s third-quarter results, ...

Analyst Stephens covers INOVIO Pharmaceuticals highlighting its diverse clinical pipeline and FDA's consideration of INO-3107 Phase 1/2 trials for Accelerated Approval. Potential as the first non ...

Shares of Inovio Pharmaceuticals Inc. INO slipped 2.91% to $4.01 Tuesday, on what proved to be an all-around favorable ...

Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting ...

Inovio Pharmaceuticals (NASDAQ:INO – Free Report) had its price objective cut by Royal Bank of Canada from $7.00 to $6.00 in ...

H.C. Wainwright analyst Ram Selvaraju has reiterated their neutral stance on INO stock, giving a Hold rating on November 14.Don't Miss our ...

Inovio Pharmaceuticals (INO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Roy ...

Short interest in Inovio Pharmaceuticals Inc (NASDAQ:INO) increased during the last reporting ... on the decline of Inovio Pharmaceuticals's stock. Short interest data is updated every two weeks.

Inovio Pharmaceuticals (NASDAQ: INO) Q3 2024 Earnings Call Nov 14, 2024, 4:30 p.m. ET ...

PLYMOUTH MEETING, Pa. (AP) — PLYMOUTH MEETING, Pa. (AP) — Inovio Pharmaceuticals Inc. (INO) on Thursday reported a loss of $25.2 million in its third quarter. On a per-share basis, the ...